MDS Virtual Congress 2021 » Huntington's Disease

Meeting: MDS Virtual Congress 2021

A screening tool to assess telehealth suitability among patients with Huntington’s disease

S. Lee, L. Hale, K. Mcdonell (Nashville, USA)

Akinetic-rigid motor presentation among adult-onset HD participants in Enroll-HD

A. Vishnu, M. Guttman, C. Mariotti, J. Corey-Bloom, L. Jones, F. Walker, K. Marder, S. Kwak, K. Becanovic, N. Ghosh, S. Sathe, C. Sampaio (White Plains, USA)

An unusual case of belly dancer´s dyskinesia in a man with Huntington disease

S. Rodriguez Navas, E. García Roldán, D. Macías-García, A. Vilches Guerra, FJ. Palomar-Simón, F. Carrillo, M. Ruiz-Veguilla, P. Mir (Sevilla, Spain)

Atypical gait in a patient with Huntington’s Disease (HD): Functional movement disorders in the spectrum of motor phenotypes in HD

H. Leal Bailey, K. Block, E. Furr-Stimming, S. Chandra (Houston, USA)

Automatic and objective speech analysis in Huntington disease

J. Adams, E. Dorsey, M. Coffey, M. Pawlik, C. Tarolli, R. Schneider, B. Najafi, H. Zhou, A. Vaziri, H. Nguyen (Rochester, USA)

Brain MRI Cortical Atrophy correlation to clinical onset in Huntington’s Disease

H. Estrada-Rodriguez, JD. Garcia-Romero, MA. Muñuzuri-Camacho, RA. Abundes-Corona, DD. Vásquez Guevara, LM. Gaibor Noboa, A. Cervantes-Arriaga, M. Rodriguez-Violante (Mexico City, Mexico)

Burden of illness among US Medicare beneficiaries with late-onset Huntington’s disease

J. Ta, S. Reiss Reddy, E. Chang, A. Exuzides, R. Gandhy, G. Yohrling (South San Francisco, USA)

Characterising the incidence of comorbidities, hospitalisations, and death in patients diagnosed with Huntington’s disease: A cohort study of linked Swedish National Registries (2002-2019)

H. Furby, S. Moore, A. Nordstroem, R. Houghton, D. Lambrelli, S. Graham, P. Svenningsson, A. Petersen (Welwyn Garden City, United Kingdom)

Characterizing Racial and Ethnic Diversity Among Enroll-HD Participants in the US and Canada

N. Dahodwala, V. Sung, P. Gonzalez-Alegre, E. Korner, A. Patel, J. Ko, J. Ta, J. Sanchez-Ramos (Philadelphia, USA)

Characterizing US Healthcare Delivery in Huntington’s Disease (HD)

L. Seeberger, J. Corey-Bloom, M. O'Brien, P. Chen, B. Griffin, D. Schlang, D. Slowiejko (Aurora, USA)

Comparison of correlations of structural magnetic resonance imaging measures with smartphone-based active tests and clinical tests in Huntington’s disease

J. Rennig, D. Hawellek, J. Dorn, F. Lipsmeier, S. Holiga, C. Simillion, S. Schobel, M. Lindemann (Basel, Switzerland)

Cost of Predictive Genetic Testing for Huntington’s Disease at Centers of Excellence in the US

M. Massey, T. Orem, V. Sung (Birmingham, USA)

Cumulative Real-World Experience with Deutetrabenazine for Huntington’s Disease Chorea at a Single Center of Excellence in the US

K. Curtis, B. Denson, V. Sung (Birmingham, USA)

Development of the Huntington’s Disease Integrated Staging System (HD-ISS)

S. Tabrizi, S. Schobel, E. Gantman, A. Mansbach, B. Borowsky, P. Konstantinova, T. Mestre, A. Mullin, J. Panagoulias, K. Romero, C. Ross, S. Sivakumaran, E. Turner, M. Zauderer, J. Long, C. Sampaio (London, United Kingdom)

Diabetes Mellitus in Huntington’s disease. The Argentinean perspective

N. Gonzalez Rojas, M. Cesarini, J. Etcheverry, E. Gatto (Buenos Aires, Argentina)

DNA methylation of CDKN2B/CDKN2B-AS1 enhancer in Huntington’s disease and lung cancer

I. Goncharova, E. Bragina, D. Gomboeva, N. Babushkina, A. Markov, M. Nazarenko, M. Nikitina, V. Alifirova, N. Zhukova, S. Illarioshkin, V. Puzyrev (Tomsk, Russian Federation)

Evaluation of CSF Assay usability for Huntington’s Disease (HD) Clinical Studies (mHTT, tHTT and NFL in HDClarity)

D. Langbehn, D. Macdonald, C. Sampaio, A G. Ehrhardt (Iowa City, USA)

Evolving inclusion criteria in early manifest Huntington’s disease (HD) to address striatal atrophy: Lessons from HD-GeneTRX-1, the first gene therapy trial

E. Furr-Stimming, C. Testa, P. Larson, C. Ross, R. Lonser, A. Samii, D. Cooper, S. Ying, M. Clarkin, E. Sawyer, R. Reilmann (Houston, USA)

Extending the spectrum of non-motor symptoms in pre-motor Huntington’s disease – a pilot study

B. Heim, D. Valent, F. Carbone, S. Spielberger, F. Krismer, A. Djamshidian, K. Seppi (Innsbruck, Austria)

Fine-grained prediction of Huntington’s disease stage using a meta-model approach

M. Kohli, S. Gregory, R. Scahill, S. Tabrizi, D. Alexander, P. Wijeratne (London, United Kingdom)

Genetic features and long-term outcome of Korean patients with Huntington’s disease.

YS. Hwang, SY. Jo, SH. Lee, SJ. Chung (Seoul, Republic of Korea)

Healthcare utilization in individuals with late onset versus adult-onset Huntington’s disease

J. Ta, TM. To, A. Patel, I. Abbass, S. Arndorfer, R. Ghandy (South San Francisco, USA)

Impaired saccadic inhibition in Huntington mutation carriers

P. Ellmerer, F. Carbone, B. Heim, M. Ritter, M. Peball, S. Spielberger, K. Seppi, A. Djamshidian (Innsbruck, Austria)

Neural oscillations modulation during working memory in premanifest and early Huntington’s disease

G. Bonassi, M. Semprini, P. Mandich, L. Trevisan, R. Marchese, G. Lagravinese, F. Barban, E. Pelosin, M. Chiappalone, D. Mantini, L. Avanzino (Genova, Italy)

Nonmotor Symptoms in Huntington disease in relation to the Diagnostic Confidence Level

N. Rocha, M. Edmondson, C. Testa, J. Patino, M. Rossetti, A. Teixeira, E. Furr Stimming (Houston, USA)

Proof-of-concept study testing bevantolol (SOM3355) as treatment of chorea in Huntington’s disease

J. Gamez, M. Calopa, E. Muñoz, A. Ferré, O. Huertas, K. Mcallister, N. Reig, C. Scart-Grès, R. Insa, J. Kulisevsky (Barcelona, Spain)

Quantifying Tremor in the R6/2 Mouse model of Huntington’s Diease

H. Skelton, D. Grogan, J. Rubiano, R. Gross, C. Gutekunst (Atlanta, USA)

Risk and timing of manifest Huntington’s disease in patients with reduced penetrance alleles

E. Mcdonnell, Y. Wang, K. Marder (New York, USA)

Syntactic and Theory of Mind difficulties in Huntington’s disease

A. Nuzzi (Bari, Italy)

The Huntington’s Disease Structured Interview of Function (HD-SIF): A remotely administered caregiver interview for later stage HD

M. Roche, R. Fuller, L. Cherneski, O. Handley, S. Capodarca, E. Neacy, S. Frank, G. Stebbins, S. Sathe, C. Sampaio (Princeton, USA)

Using Human Neural Tissue Methylation to Decipher Epigenetic Characteristics and Cell Type Pathologies in Huntington’s Disease

A. Glaser, J. Levy, Z. Zhang, L. Salas (Hanover, USA)

Using patient-reported quality of life outcomes to assess the validity of smartphone-based remote assessment of motor and cognitive performance in manifest Huntington’s disease patients

F. Riese, J. Rennig, F. Lipsmeier, A. Bamdadian, S. Schobel, C. Gossens, P. Weydt, J. Dorn, E. Wild, D. Trundell, C. Simillion, M. Lindemann (Basel, Switzerland)

Validation of biomarkers in Huntington’s disease to support the development of disease-modifying therapies: a systematic review and critical appraisal scheme

H. Tang, T. van Eimeren, C. Sampaio, T. Mestre (Ottawa, Canada)